Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyinosinic-polycytidylic acid + CpG oligodeoxynucleotide
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Sciences
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intranasal, Intravesical, Subcutaneous
01
Overview
Polyinosinic-polycytidylic acid (poly I:C) combined with CpG oligodeoxynucleotide (CpG ODN) is an experimental, unapproved combination of two nucleic-acid immune adjuvants. Poly I:C is a synthetic double-stranded RNA analogue that acts as a Toll-like receptor 3 (TLR3) agonist, while CpG ODN is a synthetic single-stranded DNA oligonucleotide with unmethylated CpG motifs that acts as a Toll-like receptor 9 (TLR9) agonist. Together, they function as synergistic immunostimulants that activate innate and adaptive immune pathways. This combination has been investigated preclinically as an adjuvant for therapeutic cancer vaccines (such as for HPV-related tumors and bladder cancer) and prophylactic infectious-disease vaccines (such as for *Helicobacter pylori*).
- Other names
- PIC@LNPs-CpGPIC@LPs-CpGpoly I:C + CpGpoly I:C + CpG ODNpoly(I:C) + CpGpoly(I:C) + CpG ODNpolyinosinic-polycytidylic acid + CpGpolyinosinic:polycytidylic acid + CpG oligodeoxynucleotidepolyriboinosinic-polyribocytidylic acid + CpG oligodeoxynucleotide
02
Targets
TLR3 (Toll-like receptor 3)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on polyinosinic-polycytidylic acid + CpG oligodeoxynucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyinosinic-polycytidylic acid + CpG oligodeoxynucleotide.